Innoviva, Inc.

INVA

Statistics

$14.56Share Price
$1.7 BMarket Cap
7.1%EBIT / EV
5.2%FCF / EV
67.0%ROIC
49.7%Cash ROIC
225.0%3yr Avg Revenue Growth
31.51Current Ratio
star logo

Business Model Diligence

We do not yet have Business Model Diligence for this stock.

Statistical Diligence

gray wandCurrent member of one or more spells! Log in to see which ones.
check mark The EBIT / Enterprise Value of 7.1% ranks as Above Average.
check mark The Free Cash Flow / Enterprise Value of 5.2% ranks as Above Average.
check mark The Return on Invested Capital Value of 67.0% ranks as Very High.
check mark The Cash Return on Capital Value of 49.7% ranks as Very High.
check mark The 3 Year Average Revenue Growth Value of 225.0% ranks as Very High.
check mark Near-term Financial Health appears to be Very Good. The Current Ratio is 31.51.

Company Description

Innoviva, Inc. engages in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Brisbane, CA.

Calculations

You must have a MagicDiligence Membership to view the Calculations for this stock. If you are already a member, you need to log in first.
Tracking Portfolios
blue wand Magic Recipe 29.36%
purple wand Deep Value 24.71%
orange wand Quality Growth 44.22%
green wand Green Team 6.14%
red dot Red Rating 5.76%
yellow dot Yellow Rating 14.17%
green dot Green Rating 14.95%
New Spell Stocks
blue wand Vector Group Ltd. (VGR)
purple wand New Stocks Added!